References
- Bush SP, Ruha A-M, Seifert SA, Morgan DL, Lewis BJ, Arnold TC, et al. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: A prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol (Phila) 2015; 53:37–45.
- Levine M, Ruha AM, Padilla-Jones A, Gerkin R, Thomas SH. Bleeding following rattlesnake envenomation in patients with pre envenomation use of antiplatelet or anticoagulant medications. Acad Emerg Med 2014; 21:301–307.
- Boyer LV, Chase PB, Degan JA, Figge G, Buelna-Romero A, Luchetti C, Alagón A. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab’)2 antivenoms. Toxicon 2013; 74:101–108.
- Lavonas EJ, Ruha AM, Banner W, Bebarta V, Bernstein JN, Bush SP, et al.; Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011; 11:2.
- Wade, L. For Mexican antivenom maker, US market is a snake pit. Science 2014; 343:16–17.